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1. Introduction 
Cerebral vascular diseases (CVD) are the third leading cause of death in industrialized 
countries and in Cuba affect the 50% of the population above 60 years old [1-2]. The 
mortality is exponentially increased with age and doubles every five years. A total of 22,000 
annual cases are estimated in Cuba, a country where life expectance should increase to 80 
years in the near future [1]. 
CVD are often followed by a high social and individual cost as a consequence of disability 
and family affectation. 
The most problematic among such diseases is ischemic cerebral vascular disease, 
characterized by the reduction of cerebral blood flow (CBF) below a critical level. From this 
initial event several processes take place to induce the clinical symptoms of cerebral 
ischemia [3]. 
Prioritized attention has been granted to CVD prevention in Cuba for reduction of mortality 
and morbidity indexes associated with these diseases. Risk factors and patients suffering 
from transient ischemic attacks (TIA) have received special consideration [4]. 
While most strategies, such as thrombolysis, are aimed at CBF recovery, neuroprotection 
intents to increment cell survival through the modification of the ischemic cascade [4, 5]. The 
most important therapeutic strategy in patients with ischemic stroke is directed to improve 
CBF and to reduce or block sub cellular and cellular metabolic consequences [6].  
Some proposals point to more than just a partial solution to the problem of ischemic cascade 
and call for combined therapies and the use of molecules involved in endogenous 
neuroprotection. [5-7]. A good candidate could be human recombinant erythropoietin (rHu-
EPO), which has been employed in the treatment of renal insufficiency associated anemia, 
and in cancer patients suffering anemia as a consequence of chemo and radiotherapy. The 
effect of rHu-EPO in the protection of brain cells from ischemic injury has been investigated 
during the last decade [8-14]. 
Given the systematic failures in clinical trials using proven neuroprotection ability 
molecules in animal models [16], it seems logical to reevaluate the therapeutic strategy for 
therapeutic treatment in the acute phase of stroke.  
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Searching within selected biological mechanisms for endogenous neuroprotection appears 
to be the most promising. Today this is possible by the advances science and technology 
have achieved through biotechnology, which allows us to obtain proteins similar to 
Erythropoietin to autologously use our brain to maintain homeostasis at a stroke. 
Helping this process may be the way to a successful therapeutic strategy for neuroprotection 
against stroke and general neurological diseases and inherited degenerative diseases too. 
EPO had been reported as a neuroprotective molecule in animal models with perspectives 
for its clinical use. However, systemic administration has shown potential side effects.  
For that reason, recently researchers have demonstrated neuroprotective effects in 
different animal models of stroke using EPO as a neuroprotector or other different types 
of EPO without erythropoiesis-stimulating activity. These new molecules retain their 
ability to protect neural tissue against injury and they include Asialoerythropoietin 
(asialoEPO) carbamylated EPO (CEPO), and rHu-EPO with low sialic acid content 
(Neuro-EPO). [15, 16]  
On the other hand, some of these derivatives of EPO or rHu-EPO have been shown to have 
no neuroprotective effect during in vivo studies. [17, 18] 
Indeed, nasal administration presents advantages treating the brain compared with 
intravenous and intraventricular routes, especially for treatments utilizing Neuro-EPO. [16]  
In this chapter, the authors focus on the neuroprotective effect from treatment of nasal 
Neuro-EPO in the acute stroke animals’ models and the security and efficacy of this 
treatment from the perspective of the stroke therapies.  
2. Neuroprotection and endogenous erythropoietin 
A drug sufficiently effective and with safe access to the central nervous system (CNS) has 
not been developed yet for neuroprotective treatment of neurological diseases in either 
chronic or acute stages. 
Besides, most of neuroprotective therapeutic agents, effective in ischemia biomodels, have 
failed to be clinically tolerated [19]. A strategy to circumvent this problem can be the use of 
the same molecules expressed in the brain after different lesions, [9, 20,] helping in the 
maintenance of homeostasis. 
The use of endogenous biomolecules with therapeutic activity is a recent proposal in 
neuroscience research [20]. An example of this type of molecule is erythropoietin, a 
glycoprotein produced in the kidney and involved in the proliferation, differentiation, and 
maturation of erythrocyte progenitors, increasing oxygen supply to the tissues [21]. Indeed, 
EPO is one of the molecules more conserved evolutionarily [22]. This can be interpreted, as 
the EPO molecule is affective and safe in their biological activity. 
The observation that EPO and its receptor (EPO-R) are expressed in the brain has stimulated 
the development of studies related to the neuroprotective effect of this molecule in different 
models of stroke [23, 24]. EPO expression increases during cerebral ischemia, suggesting its 
role in the endogenous neuroprotector system of the mammalian brain [25]. 
rHu-EPO is one of the ten best selling products of world biotechnology. The study of the 
neuroprotective effect of erythropoietin has been stimulated by the fact that this drug is 
normally expressed within the brain and is regulated by hypoxia inducible factor 1 (HIF-1) 
(Figure 1), which is in turn activated by a wide variety of stress factors. 
Indeed, in the last 5 years several reports of applications of rHu-EPO in cytoprotection were 
done (Table 1) 
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Fig. 1. Simplified diagram showing the main actors associated with neuronal protective 
response mediated by HIF-1. Where participating EPO, EPOR, HIF1a dimerizes with HIF-1b 
is the signal for transcription in the nucleus and results in EPO mRNA and finally to the 
synthesis of erythropoietin (EPO). 
 
Assay 
in vivo or in vitro
Models
Route/dose Reference 
In vitro 
Primary Culture of 
Astrocytes 
Rat 5-20 U/mL Diaz Z, (2005) 
Focal and global 
cerebral 
ischemia 
Mouse IP 25-100U Marti HH (2004) 
Focal Ischemia MCA Rat IN 4.8, 12, 24 U/kg Yu YP, et al (2005) 
Focal Ischemia MCA Rat IP 100, 1000, 
5000 U/kg
Belayev L et al (2005) 
Retinal Ischemia Mouse and rat IP 5000 U Grimm C, et al 2006 
Neonatal brain 
hypoxia 
Rat IP 1000 U/kg Yamada M, et al (2011) 
Spinal cord injury Mouse and rat IP 5000 U Mofidi A et al (2011) 
Focal cerebral
ischemia 
Gerbils IN 249.4 U 
Rodríguez Y et al 
(2010) 
Table 1. Some reports of applications of rHu-EPO in cytoprotection.  
U=Unit; IP= Intraperitoneal Injection; MCA=Middle Cerebral Artery; IN= Intra Nasal  
3. Brain protection by erythropoietin 
It has been demonstrated that EPO and its receptor are expressed in brain tissue and their 
expression increases during ischemia, suggesting that they are involved in an endogenous 
neuroprotective system in mammalian brain [25]. 
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The neuroprotective efficacy of rHu-EPO has been tested in several animal models of 
nervous system injury in mouse, rat, gerbil, and rabbit, including focal and global cerebral 
ischemia (Table 1), showing a reduction of neuronal death. 
Although the neuroprotective mechanism of rHu-EPO is still being investigated, it is known 
that this effect is mediated by receptors located at the walls of the vascular endothelia and 
astrocytes [26]. The neuroprotective mechanism of rHu-EPO seems to be multifactor. rHu-
EPO may indirectly mediate neuroprotection by restoring the blood supply to the injured 
tissue or acts directly over the neurons by activating multiple molecular signaling pathways. 
The rHu-EPO molecule positively modulates the expression of antioxidant enzymes and 
reduces nitric oxide mediated formation of free radicals; by a mechanism involving JAK2 
[27] and the nuclear factor NFkB [28]. Its antioxidant action is also sustained by restoring the 
cytosolic catalase and glutathione peroxidase activities in erythrocytes, which protects 
against the oxidative stress by reducing lipid peroxidation [29] and also EPO plays an 
important role in protecting against brain ischemia/reperfusion through inhibiting lipid 
peroxidation and decreasing blood brain barrier (BBB) disruption [30]. 
It has been demonstrated that rHu-EPO also displays neurotrophic activity [31], which 
implies an effect of larger latency than the inhibition of apoptosis [32] and reduces neuronal 
exitotoxicity, involved in many forms of cerebral injury. rHu-EPO has been also identified as 
a potent mediator of tolerance to ischemia [33]. 
Like other HIF-1 induced cytokines, this glycoprotein promotes angiogenesis as a response 
to hypoxia and neuronal injury [34] by stimulating the generation of microvessels through 
the interaction with its receptor in the blood vessels [35, 36]. 
Its antiapoptotic action is given through the EPOR mediated activation of JAK2, which in 
turns leads to the activation of NF-kB and to the overexpression of the apoptosis inhibiting 
genes XIAP and c-IAP2 [34]. rHu-EPO protects neurons from ischemic injury by 
overexpression of Bcl-x in the hippocampus of gerbils [29].  
At the same time it stimulates cell survival by inhibiting the MAPK and PI3K/Akt complex 
which promotes apoptosis [29]. These data suggest that rHu-EPO acts by controlling the 
balance of the expression of either pro apoptotic or antiapoptotic molecules [37]. 
The neuroprotective effect attributed to rHu-EPO can be also derived from its anti-
inflammatory effect signaling in neurons, glial and cerebrovascular endothelial cells and 
stimulates angiogenesis and neurogenesis. These mechanisms underlie its potent tissue 
protective effects in experimental models of stroke [38.] 
A summary of the different biological activities on cells of the nervous system to explain the 
cytoprotective capacity of EPO is shown in Table 2 
 
 
Activity/ Cells  
Immature
Neurons 
Neurons Astrocytes Microglia Ependimal Oligodendrocyte 
Neurogenesis YES ? ? ? ? ? 
Anti oxidative ? YES YES YES ? ? 
Tropic YES YES ? ? ? ?
Anti apoptotic YES YES YES ? YES YES 
Anti 
Inflammatory 
YES ? YES YES ? YES 
Anti-Glutamate ? YES ? ? ? ? 
Table 2. Differents neuroprotective profile for rH-EPO on cells of the nervous system.  
(?)= Not yet demonstrated activity; (YES) = Demonstrated Activity. 
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4. Delivery of drugs to CNS and BBB 
The deficiency in this first decade of the century to have efficient and safe drugs to counter 
neurodegenerative diseases and cerebrovascular accidents are, without a doubt a pressing 
need for the development of pharmacology and neuroscience in general. 
Some molecules have been developed with proven ability in different biomodels of 
neuroprotective stroke; however, none of them managed to overcome the barrier of Phase III 
clinical trials [35]. In this respect, several negative factors are limiting the success. At this 
point, we refer to the strong obstacles that represent the BBB. 
We focus our commentary on the possibilities for EPO to be one of the safest and most 
effective drugs that has developed global biotechnology. EPO has been used in millions of 
peoples for over 20 years with very few adverse effects reported. 
The application of EPO and its non-erythropoetic variants like Neuro-EPO through nasal 
delivery to the central nervous system target an area of great interest right now [39-41]. In 
cynomolgus monkeys, intra nasal route is relatively well known anatomically, physiologically 
as well as the transport mechanism of low molecular weight molecules and proteins to the 
brain [42]. 
In a simplified form the nasal cavity can be divided into three parts. They are: 1) Nasal 
vestibule, 2) Olfactory region and 3) Respiratory region (Figure 2).  
Of these three regions, drugs released into the nostril in contact with the nasal epithelium, 
which has several types of cells through the lamina propria, and a thin layer off loose 
connective tissue containing blood. Vessels, lymphatic vessels, axons and glands are 
involved. 
For a drug to travel from the olfactory region in the nasal cavity to the CSF or brain 
parenchyma has to go through the olfactory epithelium, depending on the path followed, 
also the arachnoid membrane. In principle you can consider three paths through the 
olfactory epithelium: 
• Via endocytic pathway, primarily through subtentaculares cells, where endocytosis 
processes occurring receptor-mediated endocytosis of liquid phase or by passive 
diffusion. This path corresponds especially to small lipophilic molecules or large 
molecules. 
• Via extra cellular through the tight junctions or open cracks in the membrane between 
sustentacular cells and olfactory neurons. This pathway is particularly suited to small 
hydrophilic molecules. 
• Via axonal: The drug can be transported through the olfactory neurons (where 
endocytic mechanisms enters or pinocytotic) to the olfactory bulb by axonal transport 
intracellular 
Possible mechanisms by which macromolecules applied to the nasal cavity transport to the 
brain are under investigation. 
These mechanisms are involved in several possible anatomical structures such as olfactory 
and trigeminal nerves, vasculature, cerebrospinal fluid (CSF), and the lymphatic system. 
Possible routes for the molecules of the nasal cavity to the brain may involve several 
mechanisms as bulk flow and diffusion within perineural channels, perivascular spaces, or 
lymphatic channels directly connected to brain tissue or CSF [40]. 
It is known that the trigeminal nerve innervates the nasal cavity and provides a direct 
connection to CNS, a description of these pathways and Genc (2011) in an excellent Expert 
Opinion [41] has recently reported processes. 
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We note that there are now enough experimental evidences and clinical practice show that 
the olfactory BBB level can be considered highly permeable to many molecules, including 
proteins of medium molecular weight such as erythropoietin. 
This possibility is challenges to use this route to deliver drugs to the CNS that do not allow 
access the BBB. What are the advantages and disadvantages offered by the nasal route to 
deliver molecules to the CNS will discuss below. 
 
 
Fig. 2. Diagram of the nasal cavity. Structure of olfactory epithelium with the 
communication proposed for the circulation of substances by intranasal route to the CNS 
and possible routes to come from the Neuro-EPO to the brain when applied nasally. 
5. Advantages and disadvantages of the nasal route for drug delivery to CNS 
In this section, we would point out those aspects that we believe according with our 
experience should always be taken into account for proper projection of work with a 
formulation of nasal application. 
It is truly remarkable to consider the anatomical differences between rodents and humans 
with respect to the nasal system. These become more important since most drug studies are 
conducted in rodents. 
We must also take into account the experimental general procedure in trials where it has 
demonstrated the efficacy and safety of a nasal preparation. The possible influence of 
anesthesia methods employed (mostly placed in the supine position) and experimental 
factors to try to find optimal conditions, far removed from real life human beings. 
Among the advantages of nasally is low cost, as opposed to systemically, this product does 
not require needles or syringes, which represents a negligible cost for a drug. For the same 
reason your application is easier and less traumatic and allows smooth, self-application. 
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Perhaps the biggest advantage is its rapid nasal application release to the CNS, 
concomitantly with a considerable less amount of drug applied and therefore a lower risk of 
side effects from excessive drug. 
Studies carried out in nonhuman primates using rH-EPO systemically and Neuro-EPO 
nasally, showed that Neuro-EPO was more readily to the lumbar CSF and for more longer 
time and with a considerably lower dose of Neuro-EPO.  
This study shows the distribution levels of Neuro-EPO content in CSF obtained by lumbar 
puncture at different time intervals after application intranasal (Neuro-EPO 1000 IU) or 
intravenously (rHu- EPO, 5000 IU). 
There was a peak of 430 mIU / mL for rHu-EPO at 10 min after application, representing 
approximately 0.01% the total injected dose, whereas the total volume of CSF in this species 
is 15 mL approx. This distribution of rHuEPO from blood to the CSF is consistent with those 
reported by other authors in non-human primates [42] and human [43]. This finding is 
characteristic of those components of protein origin not permeable to the BBB, but in small 
amounts or traces is present in CSF, as albumin [44]. It should be noted that these small 
amounts physiological concentrations achieved much higher baseline levels of rHu- EPO in 
the CSF action ensuring already reported neuroprotective. 
An analysis of the results in the model of M. fascicular is shows that after the first hour the 
behavior of both approaches (intranasally and intravenous) is very similar, suggesting rapid 
elimination of the molecule. This makes it possible to avoid side effects caused by an excess 
of circulating Neuro-EPO long time in the CNS [45]. 
In a study by Brines et al (2000) [46] demonstrated an application of 5000 IU / kg via 
intraperitoneal mouse EPO levels in CSF was highest 3.5 hours from application.  
Among the disadvantages we can point to the nasal route is that we can not determine with 
absolute precision the dose that each nasal application is delivered to the CNS. Another 
aspect is the exclusion of people with allergies, deviated nasal septum, the mucus and 
clearings may reduce the passage of product to the CNS. 
Among the side effects of intranasal application of erythropoietin, is the fact that most of the 
application moves into the bloodstream and therefore has the capacity to induce 
erythropoiesis, at least, increases the number of red blood cells. Any increase in these cells 
will increase the viscosity of blood, which is undesirable for patients in the acute stroke. 
Therefore, the development of non-erythropoietic variants from the ability to maintain 
protective capacity shown for erythropoietin is an emerging field within neuroscience 
comment below as variants not erythropoietic of erythropoietin and its neuroprotective 
action.  
6. Non-erythropoietic variants of erythropoietin and their neuroprotective 
action 
Recently, several different types of new EPOs without erythropoiesis-stimulating activity 
have been developed. These new molecules retain their ability to protect neural tissue 
against injury; they include Asialoerythropoietin (asialoEPO) [47,48], carbamylated EPO 
(CEPO)[49-,51], and rHu-EPO with low sialic acid content (Neuro-EPO)[16, 39,45]. 
6.1 AsialoEPO 
The need for nonerythropoietic rHu-EPO derivatives that still retain neuroprotective action 
has led to the discovery of asialoEPO, generated by total enzymatic desialylation of rHu-
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EPO. AsialoEPO has the same EPO-R affinity and neuroprotective properties as EPO, but an 
extremely short plasma half-life [50]. 
The ability to dissociate the tissue-protective actions of EPO from its erythropoietic actions 
may eventually be applied in the clinic to promote neurological regeneration without 
increasing red blood cell formation [52]. Erbayraktar and coworkers [53] have shown 
protective activities of the nonerythropoietic asialoEPO in models of cerebral ischemia, 
spinal cord compression, and sciatic nerve crush. Additionally, asialoEPO protects against 
neonatal hypoxia-ischemia as potently as EPO in hypoxic-ischemic brain injury in 7-day-old 
rats [52] and also in short-term changes in infarct volume, penumbra apoptosis and 
behaviors following middle cerebral artery occlusion in rats [48]. 
6.2 CEPO 
Another modified EPO molecule that solely manifests tissue-protective action without 
erythropoietic activity may have a more targeted effect. As an example, transformation of 
lysine to homocitrulline by carbamylation gives rise to carbamylated EPO (CEPO) [50]. 
CEPO, similar to asialoEPO, lacks erythropoietic effect, but still shows neuroprotective 
effects in animal models of stroke, diabetic neuropathy, and experimental autoimmune 
encephalomyelitis to an extent comparable to that of EPO [54]. It is important to note that 
CEPO has a minimal affinity for EPO-R and that its effects are mediated via a different EPO 
receptor. It is thought that this receptor consists of the EPO-R monomer together with a 
dimer of the common β chain (CD131). Recently, an investigation carried out in a rat model 
of focal cerebral ischemia showed that post ischemic intravenous treatment with CEPO led 
to improved functional recovery [52]. In 2007, a study by Mahmood et al. [55] assessed the 
effect of intraperitoneally infused rHu-EPO and CEPO in a traumatic brain injury rat model, 
and they concluded that rHu-EPO and CEPO are equally effective in enhancing spatial 
learning and promoting neural plasticity, but hematocrit was significantly increased only 
with rHu-EPO. Similarly, a recent study by Wang et al [52], demonstrated equivalent effects 
of rHu-EPO and CEPO in the reduction of neurological impairment in rats subjected to 
embolic middle cerebral artery occlusion (MCAO). As expected, rHu-EPO, but not CEPO, 
produced a transient increase in hematocrit levels.  
Another advantage of EPO over CEPO was demonstrated in rodents. Short-term treatment 
with EPO at doses optimal for neuroprotection caused significant alterations in platelet 
function and composition with in vivo haemostatic consequences, while CEPO treatment 
had no effect on these parameters [56]. 
6.3 Neuro-EPO 
During the biotechnological production of rHu-EPO, various isoforms with different 
contents of sialic acid are obtained. When the sialic acid content is 4–7 mol/mol protein, it is 
considered a low sialic acid–containing EPO, modified to display low sialic acid content 
(Neuro-EPO) is very similar to the one that occurs in the mammalian brain. Low sialic acid–
containing EPOs are rapidly degraded by the liver. Thus, this molecule could be 
administered by a no systemic route, such as the intranasal route, to prevent its hepatic 
degradation. The intranasal administration of Neuro-EPO has been shown to be safe; the 
molecule reaches the brain rapidly, does not stimulate erythropoiesis after acute treatments, 
and shows efficacy in some rodent models of brain ischemia and in nonhuman primates. 
This proposal could be considered a therapeutic option for stroke and others 
neurodegenerative illness. (See review García Rodriguez and Sosa Testé, 2009) [3]  
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There have been two strategies followed so far by different research groups. Some have 
postulated the safer use of erythropoietin as a neuroprotectant in cerebral ischemia. Their 
works have been based on existing knowledge of primary and secondary structure of the 
protein erythropoietin (Figure 3) and knowing there are differentially placed amino acid 
sequence with erythropoietic capacity and cytoprotective property in this cytokine.  
From this knowledge has been postulated by different chemical modifications to inactivate 
the capacity of erythropoietic region, leaving only the resulting molecules with 
neuroprotective capacity. This variant has the potential disadvantage of the molecule 
obtained in this way; it is not similar to that naturally produced by the CNS, which may 
bring difficulties in recognition or neurotoxicity. These topics have not yet been fully 
studied in works of neurotoxicology.  
The second variant, through which we get the Neuro-EPO, is characterized not by changes 
to chemical molecules produced by biotechnology, but selects those molecular populations 
with a low profile isoforms sialic acid content that make the Neuro-EPO easily degraded as 
it passes into the bloodstream. In addition, recent study has demonstrated in 
neurotoxicological study its safety and low toxicity when applied nasally [57]. 
Therefore, studies of effectiveness and efficiency are top priority. A synthetic form below 
and discussion of the work with the Neuro-nasally EPO in models of cerebral ischemia. 
 
Neuro-EPO and EPO
The representation homodimer 
rHuEPO.
Koury ST, Koury MJL: Erythropoietin production by the kidney. Semin
Nephrol 13(1):78-86, 1993
Region with neurotrophic activity.
Campana y cols, 1998.
Erbayraktar S y  col, 2003
Erythropoietic activity region
Campana y cols, 1998.
Also reported neuroprotective 
activity for carbamyl derivatives 
asialo EPO and EPO (CEPO) in 
models of cerebral ischemia
 
Fig. 3. Top Show the representation of EPO protein AA sequences and Regions with 
Neurotrophic and Erythropoietic activity. Down, Show the representation homodimer 
rHuEPO. 
www.intechopen.com
 
Acute Ischemic Stroke 
 
68
7. Security and efficacy of the nasal Neuro-EPO intra nasally preclinical 
studies of brain ischemia 
Evaluation of whether the formulation produced allowed the arrival of the Neuro-EPO 
nasally applied to the CNS was one of the first tasks accomplished. The animal model was 
the Gerbil Mongolia. (Figure 4) 
Activity detected molecule Neuro-EPO labeled I125 was detected in the olfactory bulb and 
cerebellum. In the CSF concentrations was in the range of physiological and therefore 
support an adequate therapeutic concentration. 
The nasal opening is generally favored for rodents. The nasal olfactory mucosa covers 
approximately 50% of total nasal epithelium in the rat [58], while in human’s covers only 5% 
[59]. Another important difference is the volume of cerebrospinal fluid (CSF) in the rat is 3.5 
ml and in humans is 160 ml, therefore, the replacement time of the CSF in the rat is 1.5 hours 
while in humans is 5 hours, making it difficult to infer the uptake of molecules of one 
species to another. However studies conducted on the passage of molecules by the 
intranasal route in species such as nonhuman primate Macaca fascicularis species are 
recommended for pharmacokinetic studies of the nasal [45, 60]. 
 
 
Fig. 4. Neuroprotective effects of EPO Neuro-nasal model of focal cerebral ischemia in the 
Mongolian Gerbils. In the group of animals treated with EPO Neuro-applied by nasal way 
only animals died within 24 hours. This behavior continued until 5 weeks, which 
demonstrates the powerful protective effect achieved by intranasal application of Neuro-EPO.  
The transit of Neuro-EPO to the CNS after intranasal administration and its effect were 
reported by us [41]. The detection of the molecule either in the olfactory bulbs or in the 
cerebellum suggested its contact with the CSF. This was further confirmed by the significant 
increase of rHu-EPO in the CSF of M. fascicularis (Figure 4) 5 min after its administration by 
the intranasal route. In animals treated with Neuro-EPO, a preservation of the habituation 
behavior in spontaneous exploratory activity was observed in both models, demonstrating 
the conservation of the structural integrity of the brain regions related to learning, and 
short- and long-term memory [61]. 
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In the model of MCAO for 2 h in rats, animals treated with Neuro-EPO by the intranasal 
route displayed smaller volumes of ischemic tissue and a better clinical condition at 48 h 
[62]. The results of this study in rodents show therapeutic efficacy in both the acute and 
chronic phases of ischemia, as well as in reperfusion ischemia models, suggesting 
neuroprotective effects in brain structure and function. 
These are indirect evidences of the access of Neuro-EPO administered in the amounts 
equivalent to the therapeutic dose recommended for ischemia by the intranasal route. 
Those results suggest additional advantages for the intranasal route, which could be safer 
and faster than the intravenous route, which was recently demonstrated for delivery of 
Neurotrophic factors BDNF, CNTF, EPO, and an NT-4 to the CNS. [63] 
In correlation with these ideas, Fletcher et al. [64] demonstrated that intranasal EPO plus 
IGF-I penetrate into the brain more efficiently than other drug delivery methods, and could 
potentially provide a fast and efficient treatment to prevent chronic effects of stroke. 
A general survey carried out by a group of investigators concerning the use of the intranasal 
route to administer drugs for the treatment of diseases affecting the CNS indicated that in 
the last decade, roughly 11% of the new drugs generated by the industry are administered 
by this route. Patients prefer intranasal administration due to the efficacy and safety of these 
formulations.  
A recent study assessing the safety of the Neuro-EPO was carried [57] out because the use of 
human recombinant erythropoietin (EPO) as a neuroprotective agent is limited due to its 
hematological side effects. Neuro-EPO, similar to that produced in the brain during 
hypoxia, may be used as a neuroprotective agent without risk of thrombotic events. 
The objective of this investigation was to assess the toxicological potential of a nasal 
formulation with Neuro-EPO in acute, subacute and nasal irritation assays in rats. Healthy 
Wistar rats (Cenp: Wistar) were used for the assays.  
In an irritation test, animals received 15 micro liters of Neuro-EPO into the right nostril. Rats 
were sacrificed after 24h and slides of the nasal mucosa tissues were examined. Control and 
treated groups showed signs of a minimal irritation consisting of week edema and vascular 
congestion in all animals. In the acute toxicity test, the dose of 47,143UI/kg was 
administered by nasal route. Hematological patterns, body weight, relative organ weight, 
and organ integrity were not affected by single dosing with Neuro-EPO.  
In the subacute toxicity test, Wistar rats of both sexes received 6,600 UI/kg/day for 14 days. 
The toxicological endpoints examined included animal body weight, food consumption, 
hematological and biochemical patterns, selected tissue weights, and histopathological 
examinations. An increase of lymphocytes was observed in males that were considered to 
reflect an immune response to treatment. Histopathological examination of organs and 
tissues did not reveal treatment-induced changes.  
The administration of Neuro-EPO at daily doses of 6,600 UI/kg during 14 days did not 
produce hematological side effects.  
In conclusion, these results suggest that Neuro-EPO could offer the same neuroprotection as 
EPO, without hematological side effects. 
In fact the great advantage of having a formulation of erythropoietin with neuroprotective 
capacity but non-erythropoietic enables its possible implementation, not only in the acute 
phase of stroke but in its later stage, where its behavior will give us useful information, 
possible for the treatment of chronic neurodegenerative diseases of the CNS. 
Therefore, a discussion to determine the effectiveness of the Neuro-EPO treatment in 
chronic phase of stroke model using Gerbils follows. 
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8. Nasal delivery of Neuro-EPO. Effect in acute and sub chronic phase post 
stroke in animal model 
We are relatively poorly acquainted with the effects of erythropoietin in the central nervous 
system. Therefore, our bank of knowledge with the novel nasal formulation of Neuro-EPO is 
correspondingly miniscule. 
Therefore, it is logical to want to know the effect on the CNS by administration of Neuro-
EPO by the nasal route, not just over days, but when it is applied for weeks. 
Of practical interest, it has been postulated that EPO activates mechanisms of 
neuroplasticity [65]. The mechanism through which the Neuro-EPO does this 
neuroprotective effect in the short and medium term is an issue that requires more basic 
research. In this direction a recently paper from Reitmer et al., (2011) (66) showed that EPO 
administered intra-cerebroventricularly at 10 IU/day; starting 3 days after 30 min of middle 
cerebral artery occlusion. The neurological recovery was associated with structural 
remodeling of ischaemic brain tissue, reflected by enhanced neuronal survival, increased 
angiogenesis and decreased reactive astrogliosis with expression changes of plasticity-
related molecules that facilitated contralesional axonal growth, and establishes a plasticity-
promoting effect of EPO after stroke. [66]. In this excellent work, unfortunately the route 
used to delivery EPO to the brain is not applicable to stroke patients.     
If this were verified, it would be invaluable for the treatment of patients, not only in the 
acute phase, but also for the recovery period of mental and motor activities affected by 
Stroke, using pathways and molecules safer, such as nasal delivery of Neuro-EPO. 
The protective effect of Neuro-EPO was also evaluated at short and medium term [24]. Not 
evident, at the 24-hr post ischemia time point, when the percentage of deaths in both groups 
was similar (Figure 5). However, the mortality at 48 hr after brain ischemia was greater in 
the Nasal-Vehicle group than that in the Nasal-Neuro-EPO group (p=0.02). Indeed, 50% 
more of the animals in the Nasal-Vehicle group were dead at 48 hr after ischemia, whereas 
no animals from the Nasal-Neuro-EPO group died before 48 hr post ischemia. No further 
mortality was recorded during the five weeks of the study. Among other tests, this result 
confirms the well-known phrase "Time is Brain". This expression is also valid for the nasal 
application of Neuro-EPO. 
In this study, the animals treated with Nasal-Neuro-EPO showed better general states. The 
gerbils with higher neurological scores not only showed deterioration in the extremities 
corresponding to the damaged hemisphere but also showed defects on the opposite side, 
including bilateral palpebral ptosis. The open field-testing to evaluate the exploratory 
activity of the animals showed significant differences (p<0.05) when comparing activity 
before surgery to after surgery in all groups of ischemic animals, except in the groups 
treated with Nasal-Neuro-EPO, which showed no difference. A marked behavioral 
difference existed at 24 hr between the ischemic animals in both treatment groups [24]  
These results taken together speak for the effectiveness and safety of nasally administered 
Neuro-EPO in one of the strongest models of stroke. 
The concept of achieving a significantly higher survival in animals treated with Neuro-EPO 
nasally during the 5 weeks of the study gives clear evidence of its neuroprotective 
properties. If we attach to this value the protection, which it confirms to the neurological 
status of animals, and histological protection displayed [24] we can ensure that this 
molecule has strong neuroprotective effects in the short and medium terms. However, we 
[24] recently reported its relationship with the EPOR and the expression of another 
important protein in the CNS, neuroglobin. 
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Fig. 5. The protective effect of Neuro-EPO was also evaluated at short and medium term. 
Not evident at 24-hr post ischemia time point; when the percentage of deaths in both groups 
was similar. However, no further mortality was recorded during the five weeks of the study. 
Among other tests, this result confirms establishes a survival-promoting effect of Neuro-
EPO in the treatment of acute stroke. 
In the next and final section of this chapter, we discuss the effect of Neuro-EPO application 
by nasal route in Gerbils Stroke model, and the effect on the expression of EPO receptor and 
Neuroglobin in this animal model. 
9. Neuro-EPO, EPO receptor and Neuroglobin in acute phase of stroke animal 
model 
As yet the molecular events, through which EPO makes its neuroprotective effect in the 
CNS have not been fully described. There are reports where it has been shown that the 
presence of its receptor in the hypoxic tissue is necessary for expression, which has been 
interpreted as the over-expression is necessary to trigger the molecular mechanisms of 
cytoprotection. That is, there have to be over expressed receptors for EPO and EPO existing 
in the region where these receptors are expressed.  
The foregoing, that is the theoretical basis of EPO supplementation to hypoxic tissue as the 
tissue damage, mainly in the so-called ischemic penumbra region, within the mechanisms of 
endogen neuroprotection is the expression of new receptors to cells.  
In addition, EPO has been shown to have the ability to induce the formation of new 
receptors. The latter should be a possible tipping point for the analysis of Neuro- EPO 
optimal dose, to avoid unwanted effects on the CNS in long-term treatment.  
This apparent paradox of the EPO receptor should be carefully studied in the future and if 
in real terms for the stress neurons as a penumbra, on the limited availability to generate 
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energy by synthesis of new receptors to the EPO. It is a challenge to the classical concept of 
cellular economy. Therefore, obviously there must exist important new functions, the EPOR, 
which we have not been able to elucidate to the present. Among them may be the 
establishment of the new homeostasis, given the change of surroundings and intrinsically in 
those neuron-specific functions in the new contact of damaged tissue.  
As complicated and not well-recognized biochemical processes of brain endogenous 
neuroprotection has emerged a relatively new protein that has been investigated by several 
research groups, we refer to neuroglobin (NGB). In the well-studied evolutionary branch of 
globins, hemoglobin has played a critical role in all vertebrates and their evolutionary 
adaptation to the oxygen atmosphere. 
At this point, we must not forget that oxygen is the final acceptor in the respiratory chain 
and the key atom of the vital energy production in mitochondria in the cells. We have long 
conceived that this step has been free of oxygen and is therefore a thermodynamically 
favored process. 
But what happens in critical conditions where there really is not enough oxygen? A few 
possibilities can be unwanted interaction with the simple entry of oxygen into a cell under 
stress or normal. These and many more are questions that motivated us to study the 
expression patterns of NGB and EPOR in the Cerebral Cortex and Hippocampus revealed 
distinctive intranasal delivery of therapeutic effects of EPO for neuro-ischemic insults to the 
gerbil brain. Later, we discuss results of this work [24]. 
Indeed, our results [24] not only showed that the intranasal delivery of Neuro-EPO is a 
valuable neuroprotective approach for the treatment of ischemia but also suggested that 
Ngb and the EPO/EPOR system have a close relationship with ischemic insults and Neuro-
EPO treatment.  
Ngb may act as a positive neuroprotective biomarker for brain ischemic insults or brain 
protection in vertebrates, including humans [68]. Thus, the overall expression patterns of 
Ngb at different time points after ischemic insults suggested that it might be an indicator of 
the neuroprotective action of Neuro-EPO in the brain (Table 3). 
Actually, recent studies have also reported that treatment with EPO after brain ischemia 
could up-regulate Ngb expression in the brain [67-70], concurring with our work. 
Furthermore, the neuroprotective effects of EPO have various complementary actions, 
including antagonism of the effects of glutamate, increased expression of antioxidant 
enzymes, changes in the production of neurotransmitters, and induction of Ngb [70]. 
In addition, we have recently demonstrated that Ngb has antioxidant and free-radical 
scavenging activities, providing fundamental evidence for the neuroprotective function of 
this protein [70]. Therefore, the neuroprotective functions of Ngb and EPO/EPOR in the 
brain are probably closely related [24].  
The dramatic expression pattern of endogenous Ngb and EPOR is possibly important for 
improving gerbil survival with intranasal Neuro-EPO treatment. EPO played a 
neuroprotective role mediated by EPOR accompanied with Ngb up regulation.  
In addition, the distinctive biphasic expression patterns of Ngb in the gerbil brain are largely 
associated with ischemic tolerance in the cerebral cortex and ischemic sensitivity in the 
hippocampus. These data are important for understanding the different reaction properties 
of different brain regions, which are subjected to ischemic insults at specific time points and 
also important for improving the therapeutic effects of intranasal Neuro-EPO 
administration. 
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Time post 
ischemic Insults 
10min 1hr 12hr 24hr 48r 72hr 1Week 
5 
Weeks 
Protein 
Brain 
Region 
        
Ngb CC - + + + - + + + 
 HP + - - - + ND + + 
EPOR CC ND - - - + ND ND ND 
 HP + - - - + - - + 
         Golden Hour                          Silver days    Late recovery Phase 
CC= Cerebral Cortex; HP= Hippocampus; EPOR= EPO receptor; ND= not determined;  
(+) = Upregulation; (-) = Down regulation. All cases p<0.05. Gold Hours is the practical more important 
time “Time is Brain”. The Silver day it is critical period of time. The 10 min and 48 hr seemed to be two 
time points for the brain to switch the expression of both Ngb and EPOR to early and late recovery 
phase, respectively. In addition, there were two phases, 10 min to 1 hr and 24 hr to 72 hr, respectively, 
closing to the “golden hour” of about 60 min and the “silver day” of 1 to 3 days, for the brain to recover 
from stroke onset with intranasal Neuro-EPO treatment. 
Table 3. Expression Pattern of Ngb and EPOR in the Cerebral Cortex and Hippocampus of 
Gerbils in the Nasal-Neuro-EPO Group Compared to Nasal-Vehicle group. Data Represent 
of 3 independent experiments. 
10. Conclusions 
There is a significant amount of histologic findings, behavioral, biochemical and 
pharmacological to support Neuro-EPO by nasal route as a neuroprotective therapy in brain 
ischemia. Unlike other molecules of EPO, which have no capability for erythropoiesis yet 
retain their neuroprotective capacity, the Neuro-EPO is not a carrier of chemical alterations 
that may cause unwanted effects, when in contact with the CNS. 
Various studies have not identified adverse effects and it has been shown to be safe and 
effective in protecting cortical regions and sub cortical hypoxic brain 18 hours after the 
occurrence of hypoxia in models where the effect has been studied. 
Evaluation of its safety and effectiveness in the clinic is the new challenge is to address 
Neuro-EPO nasally as a new neuroprotective drug to combat ischemic acute stroke. 
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